Opicapone (BioDeep_00001871373)
代谢物信息卡片
Opicapone
化学式: C15H10Cl2N4O6 (411.997738)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
InChI: InChI=1S/C15H10Cl2N4O6/c1-5-10(13(17)20(24)6(2)11(5)16)14-18-15(27-19-14)7-3-8(21(25)26)12(23)9(22)4-7/h3-4,22-23H,1-2H3
描述信息
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
D004791 - Enzyme Inhibitors > D065098 - Catechol O-Methyltransferase Inhibitors
N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:134699
- PubChem: 135565903
- DrugBank: DB11632
- ChEMBL: CHEMBL1089318
- CAS: 923287-50-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Cells.
2022 04; 11(9):. doi:
10.3390/cells11091511. [PMID: 35563817] - Ana I Loureiro, Carlos Fernandes-Lopes, Maria João Bonifácio, Filipa Sousa, László E Kiss, Patricio Soares-da-Silva. Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping.
Pharmacology research & perspectives.
2022 02; 10(1):e00891. doi:
10.1002/prp2.891. [PMID: 34939338] - Wei Xue, Yan Tan, Yue Liu, Changjiang Xu, Duanduan Cong, Liping Zhong, Jie Song, Aimin Hui, Wenyuan Qi, Juan Wang, Xiaohui Liu, Kexin Li. Pharmacokinetics of Opicapone and Its Metabolites in Healthy White and Chinese Subjects.
Clinical pharmacology in drug development.
2021 11; 10(11):1316-1324. doi:
10.1002/cpdd.922. [PMID: 33864709] - Daniel A Hussar. New Drugs 2021, Part 2.
Nursing.
2021 Oct; 51(10):18-29. doi:
10.1097/01.nurse.0000791756.56705.dd. [PMID: 34580258] - Peter Jenner, José-Francisco Rocha, Joaquim J Ferreira, Olivier Rascol, Patrício Soares-da-Silva. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone.
Expert review of neurotherapeutics.
2021 09; 21(9):1019-1033. doi:
10.1080/14737175.2021.1968298. [PMID: 34525893] - Maria João Bonifácio, Filipa Sousa, Patrício Soares-da-Silva. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
European journal of pharmacology.
2021 Feb; 892(?):173742. doi:
10.1016/j.ejphar.2020.173742. [PMID: 33220276] - Masahiro Nomoto, Atsushi Takeda, Katsuaki Iwai, Akihisa Nishimura, Nobutaka Hattori. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
Clinical pharmacology in drug development.
2021 02; 10(2):180-189. doi:
10.1002/cpdd.799. [PMID: 32416054] - Miren Ettcheto, Oriol Busquets, Elena Sánchez-Lopez, Amanda Cano, Patricia R Manzine, Ester Verdaguer, Jordi Olloquequi, Carme Auladell, Jaume Folch, Antoni Camins. The preclinical discovery and development of opicapone for the treatment of Parkinson's disease.
Expert opinion on drug discovery.
2020 09; 15(9):993-1004. doi:
10.1080/17460441.2020.1767580. [PMID: 32450711] - Takashi Kitajima, Shintaro Mizote, Maria João Bonifácio, Takeo Umemura, Kazuhiro Yoneda, Paul Moser, Patrício Soares-da-Silva, Makoto Tanaka. Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.
Neuropharmacology.
2018 12; 143(?):282-288. doi:
10.1016/j.neuropharm.2018.10.001. [PMID: 30290160] - Marina Svetel, Aleksandra Tomić, Nikola Kresojević, Vladimir Kostić. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
Expert opinion on drug metabolism & toxicology.
2018 Mar; 14(3):353-360. doi:
10.1080/17425255.2018.1430138. [PMID: 29345156] - Daniela Gonçalves, Gilberto Alves, Ana Fortuna, Maria João Bonifácio, Patrício Soares-da-Silva, Amílcar Falcão. A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.
Neuropharmacology.
2017 Oct; 125(?):146-155. doi:
10.1016/j.neuropharm.2017.07.019. [PMID: 28734868] - Daniela Gonçalves, Gilberto Alves, Ana Fortuna, Patrício Soares-da-Silva, Amílcar Falcão. Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.
Toxicology and applied pharmacology.
2017 05; 323(?):9-15. doi:
10.1016/j.taap.2017.03.013. [PMID: 28322896] - José-Francisco Rocha, Joaquim J Ferreira, Amílcar Falcão, Ana Santos, Roberto Pinto, Teresa Nunes, Luis Almeida, Patrício Soares-da-Silva. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Clinical pharmacology in drug development.
2016 May; 5(3):232-40. doi:
10.1002/cpdd.217. [PMID: 27163503] - Daniela Gonçalves, Gilberto Alves, Ana Fortuna, Patrício Soares-da-Silva, Amílcar Falcão. Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices.
Biomedical chromatography : BMC.
2016 Mar; 30(3):312-22. doi:
10.1002/bmc.3550. [PMID: 26147707] - Amílcar Falcão, José Francisco Rocha, Ana Santos, Teresa Nunes, Patrício Soares-da-Silva. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects.
Clinical pharmacology in drug development.
2016 Mar; 5(2):150-61. doi:
10.1002/cpdd.213. [PMID: 27138028] - M J Bonifácio, L Torrão, A I Loureiro, P N Palma, L C Wright, P Soares-da-Silva. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
British journal of pharmacology.
2015 Apr; 172(7):1739-52. doi:
10.1111/bph.13020. [PMID: 25409768] - José-Francisco Rocha, Amílcar Falcão, Ana Santos, Roberto Pinto, Nelson Lopes, Teresa Nunes, Lyndon C Wright, Manuel Vaz-da-Silva, Patrício Soares-da-Silva. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
European journal of clinical pharmacology.
2014 Sep; 70(9):1059-71. doi:
10.1007/s00228-014-1701-2. [PMID: 24925090] - José Francisco Rocha, Ana Santos, Amílcar Falcão, Nelson Lopes, Teresa Nunes, Roberto Pinto, Patrício Soares-da-Silva. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
European journal of clinical pharmacology.
2014 Mar; 70(3):279-86. doi:
10.1007/s00228-013-1602-9. [PMID: 24271646] - José Francisco Rocha, Luis Almeida, Amílcar Falcão, P Nuno Palma, Ana I Loureiro, Roberto Pinto, Maria João Bonifácio, Lyndon C Wright, Teresa Nunes, Patrício Soares-da-Silva. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.
British journal of clinical pharmacology.
2013 Nov; 76(5):763-75. doi:
10.1111/bcp.12081. [PMID: 23336248] - Daniela Gonçalves, Gilberto Alves, Ana Fortuna, Patrício Soares-da-Silva, Amílcar Falcão. An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma.
The Analyst.
2013 Apr; 138(8):2463-9. doi:
10.1039/c3an36671e. [PMID: 23476919] - Luis Almeida, José Francisco Rocha, Amílcar Falcão, P Nuno Palma, Ana I Loureiro, Roberto Pinto, Maria João Bonifácio, Lyndon C Wright, Teresa Nunes, Patrício Soares-da-Silva. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.
Clinical pharmacokinetics.
2013 Feb; 52(2):139-51. doi:
10.1007/s40262-012-0024-7. [PMID: 23248072]